ReceptoPharm
ReceptoPharm Homepage Contact Us Site Map
 
Products & Pipeline About ReceptoPharm Investor Relations
Developing Drugs to Save Lives

Welcome to ReceptoPharm

ReceptoPharm is an innovative biopharmaceutical research and development company developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases in humans. The emphasis of ReceptoPharm's approach to drug discovery and the development of new therapeutic agents is based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra.

ReceptoPharm has 2 Leading Drug Candidates:

  • RPI-MN inhibits the entry of several viruses that are known to cause severe neurological damage in such diseases as rabies, encephalitis, and AIDS. It is being developed first for the treatment of HIV.

  • RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).

Based upon ReceptoPharm's positive in-vitro and in-vivo data, it is planned to move into full regulatory trials as quickly as possible.

View Complete Pipeline »

 
 
Recent News
August 6, 2008
Nutra Pharma Announces Collaborative Agreement with Centers for Disease Control and Prevention (CDC)


August 1, 2008
August 2008 Shareholder Letter from Chairman and CEO Rik J. Deitsch


July 29, 2008
Nutra Pharma Announces Completion of Clinical Study in Adrenomyeloneuropathy (AMN)


 
Pipeline